529 filings
Page 4 of 27
DEFA14A
CTXR
Citius Pharmaceuticals Inc
22 Dec 22
Additional proxy soliciting materials
4:37pm
DEF 14A
CTXR
Citius Pharmaceuticals Inc
Definitive proxy
22 Dec 22
4:35pm
10-K
2022 FY
CTXR
Citius Pharmaceuticals Inc
Annual report
22 Dec 22
4:30pm
8-K
CTXR
Citius Pharmaceuticals Inc
1 Dec 22
Other Events
4:15pm
8-K
CTXR
Citius Pharmaceuticals Inc
21 Nov 22
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
9:15am
4/A
CTXR
Citius Pharmaceuticals Inc
15 Nov 22
Citius Pharmaceuticals / Leonard L Mazur ownership change
4:05pm
4
CTXR
Citius Pharmaceuticals Inc
6 Oct 22
Citius Pharmaceuticals / William Kane ownership change
4:10pm
4
Dutia Suren G
6 Oct 22
Citius Pharmaceuticals / Suren G Dutia ownership change
4:09pm
4
CTXR
Citius Pharmaceuticals Inc
6 Oct 22
Citius Pharmaceuticals / MYRON Z HOLUBIAK ownership change
4:08pm
4
CTXR
Citius Pharmaceuticals Inc
6 Oct 22
Citius Pharmaceuticals / Leonard L Mazur ownership change
4:08pm
4
Jaime Bartushak
6 Oct 22
Citius Pharmaceuticals / Jaime Bartushak ownership change
4:07pm
4
CTXR
Citius Pharmaceuticals Inc
6 Oct 22
Citius Pharmaceuticals / HOWARD SAFIR ownership change
4:07pm
4
Holuka Eugene Myron
6 Oct 22
Citius Pharmaceuticals / Eugene Myron Holuka ownership change
4:06pm
4
Webb Carol
6 Oct 22
Citius Pharmaceuticals / Carol Webb ownership change
4:06pm
4
Myron Czuczman
6 Oct 22
Citius Pharmaceuticals / Myron Czuczman ownership change
4:05pm
8-K
CTXR
Citius Pharmaceuticals Inc
28 Sep 22
Other Events
4:05pm
8-K
CTXR
Citius Pharmaceuticals Inc
22 Sep 22
I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients
4:45pm
8-K
CTXR
Citius Pharmaceuticals Inc
11 Aug 22
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
4:45pm
10-Q
2022 Q3
CTXR
Citius Pharmaceuticals Inc
Quarterly report
11 Aug 22
4:26pm
25-NSE
CTXR
Citius Pharmaceuticals Inc
8 Aug 22
Exchange delisting
4:51pm